Literature DB >> 7107981

Pharmacokinetics of erythromycin in normal and alcoholic liver disease subjects.

K W Hall, C H Nightingale, M Gibaldi, E Nelson, T R Bates, A R DiSanto.   

Abstract

The objective of this study was to compare the pharmacokinetic behavior of erythromycin in normal volunteers with that in subjects with alcoholic liver disease. Six normal volunteers received 500 mg erythromycin as an intravenous infusion or as two 250-mg enteric-coated tablets in a crossover fashion. The pharmacokinetics of erythromycin after intravenous administration was best described as a two-compartment model. The elimination half-life was 1.6 +/- 0.7 hours (mean +/- S.D.) after the intravenous dose and 2.0 +/- 0.7 hours after the oral dose. In patients with alcoholic liver disease the elimination half-life after oral administration of two 250-mg enteric-coated tablets was 3.2 +/- 0.5 hours, significantly different from that in normal subjects, probably due to impaired metabolism. The difference in half-life does not require dosage adjustment in this patient population. The systemic availability of erythromycin was 33.5 per cent (range 10.5 to 79.3 per cent).

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7107981     DOI: 10.1002/j.1552-4604.1982.tb02682.x

Source DB:  PubMed          Journal:  J Clin Pharmacol        ISSN: 0091-2700            Impact factor:   3.126


  6 in total

Review 1.  Clinical pharmacokinetic properties of the macrolide antibiotics. Effects of age and various pathophysiological states (Part II).

Authors:  P Periti; T Mazzei; E Mini; A Novelli
Journal:  Clin Pharmacokinet       Date:  1989-05       Impact factor: 6.447

Review 2.  Guide to drug dosage in hepatic disease.

Authors:  N M Bass; R L Williams
Journal:  Clin Pharmacokinet       Date:  1988-12       Impact factor: 6.447

3.  Pharmacokinetics of erythromycin in patients with severe cirrhosis. Respective influence of decreased serum binding and impaired liver metabolic capacity.

Authors:  J Barre; A Mallat; J Rosenbaum; L Deforges; G Houin; D Dhumeaux; J P Tillement
Journal:  Br J Clin Pharmacol       Date:  1987-06       Impact factor: 4.335

4.  Bioavailability of erythromycin acistrate from hard gelatin capsules containing sodium bicarbonate.

Authors:  M Marvola; S Nykänen; M Nokelainen
Journal:  Pharm Res       Date:  1991-08       Impact factor: 4.200

5.  Drug interactions with zidovudine phosphorylation in vitro.

Authors:  P G Hoggard; G J Veal; M J Wild; M G Barry; D J Back
Journal:  Antimicrob Agents Chemother       Date:  1995-06       Impact factor: 5.191

6.  Pharmacokinetic advantages of erythromycin estolate over ethylsuccinate as determined by high-pressure liquid chromatography.

Authors:  D Croteau; M G Bergeron; M LeBel
Journal:  Antimicrob Agents Chemother       Date:  1988-04       Impact factor: 5.191

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.